



Prague, 18 November 2021

Ref. No.: MZDR 47828/2020-31/MIN/KAN  
MZDRX01IAHVF

## EXTRAORDINARY MEASURE

The Ministry of Health, as the competent administrative authority pursuant to Section 80(1)(g) of Act No. 258/2000 Coll., on Public Health Protection and amendments to Certain Related Acts, as amended (hereinafter referred to as “Act No. 258/2000 Coll.”), orders this Extraordinary Measure, proceeding pursuant to Section 69(1)(i) and (2) of Act No. 258/2000 Coll., to protect the population and prevent the occurrence and spread of COVID-19 caused by the novel SARS-CoV-2 coronavirus:

### I.

Effective from 12:00 a.m. of 22 November 2021, all healthcare service providers that perform examinations to stipulate the presence of the SARS-CoV-2 virus using RT-PCR tests are ordered to perform examinations to stipulate the presence of the SARS-CoV-2 virus using RT-PCR tests on the persons specified in Art. II, who participate in the public health insurance system in the Czech Republic, if they request the performance of an antigen test and present their insurance ID card or substitute document, specifically in the case of the persons set forth in Art. II(a) through (c), no more than five times per calendar month, and in the case of the persons specified in Art. II(d) no more than twice per month.

### II.

The persons for whom an examination pursuant to Art. I is performed at their request are:

- a) persons under 18 years of age,
- b) persons who cannot be vaccinated against COVID-19 due to contra-indications; they are obliged to demonstrate this fact to the healthcare service provider performing the examination by means of a record in the Information System of Infectious Diseases (ISIN) containing express information that the person cannot be vaccinated against COVID-19 for health reasons, or a medical report containing explicit information about the fact that the person cannot be vaccinated against COVID-19 for medical reasons, and that this fact is listed in the Information System of Infectious Diseases (ISIN),
- c) persons vaccinated against COVID-19, if
  - i) a period of 14 days has not passed since application of the first dose of the vaccine in the case of a one-dose scheme based on the summary of product characteristics (hereinafter the “SPC”) as at the date of the request to perform the test, or in the case of a two-dose scheme pursuant to the SPC, they have not yet been given the second dose of the vaccine and the maximum period stipulated for application of the second dose of the vaccine pursuant to the SPC has not passed as at the date of the request to perform the test, or
  - ii) a period of 14 days has not passed since application of the second dose of the vaccine in the case of a two-dose scheme based on SPC as at the date of the

request to perform the test;

they are obliged to demonstrate this fact to the healthcare service provider performing the test,

- d) persons vaccinated against COVID-19 who submit a national certificate of performed vaccination or a certificate of performed vaccination issued pursuant to the European Union regulation on the EU COVID digital certificate, under the condition that at least 14 days have passed since the completion of the vaccination program; a national certificate of completed vaccination refers to a written confirmation issued at least in the English language by the authorized entity operating in a third country, a specimen of which is published in the list of recognized national certificates on the website of the Ministry of Health; the written confirmation must contain data about the vaccinated person, administered type of vaccine, date of administration of the vaccine, identification of the entity that issued the confirmation of that vaccination, whereas these data must be verifiable via remote access directly from the written confirmation, assuming the vaccination was performed using
- i) a medicinal product containing a COVID-19 vaccine granted market authorization under Regulation (EC) No. 726/2004, or
  - ii) a medicinal product manufactured in accordance with a patent for the medicinal product pursuant to point i), if this medicinal product has been approved by the World Health Organization for emergency use.

### III.

For the purposes of Act No. 48/1997 Coll., on Public Health Insurance and on the amendment and supplementation of certain related laws, as amended, this measure is considered to be a measure against infectious disease pursuant to Section 30(1) of the same act.

### IV.

Effective from 12:00 a.m. of 22 November 2021, this Extraordinary Measure repeals the Extraordinary Measure of the Ministry of Health of 22 October 2021, Ref. No. MZDR 47828/2020- 30/MIN/KAN.

---

**Mgr. et Mgr. Adam Vojtěch, MHA, undersigned**  
Minister of Health